Invest in the next-generation of home testing.
Providing earlier warnings on health anomalies, including cancer
DISCOUNTED SHARE OFFER:
Discounted price £3 ($3.80)
Current value $10
Projected post listing $20
Please enter your details to request more information
The global home care testing market size was valued at USD 9.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2030
Sir Eric PeacockNon Executive Chairman
Sir Eric Peacock was formerly a Non-Executive Director at the governments, United Kingdom Export Finance Company. He has previously sat on a number of other government boards, namely United Kingdom Trade and Investment. Sir Eric was knighted in 2003 for his services to International Trade.
Jack Kaye Chief
Executive Officer
Jack is a successful serial entrepreneur and has a history of identifying, developing and leading successful businesses from a start-up position. He has held, and currently holds, several executive positions, including CEO on the boards of several Companies in both Europe and North America
In the News
Davion enters into agreement with The Bank of New York Mellon for ADR programme and $30 million IPO fundraise.
Davion grants Global Manufacturing and Distribution Licence of its BreastCheck ™ home test for Breast Anomalies to NeuRX Health Inc for $120m USD
To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to us contacting you via these methods. Privacy Policy
Disclaimer: Any person accessing the email and considering potential investment opportunities featured on the email should make their own commercial assessment after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable only for sophisticated or high net worth investors. This opportunity is only suitable for high net worth or self-sophisticated investors as defined below. Either; have an annual income in excess of £100K have net assets in excess of £250K beyond your pension fund assets and your private residence. You have been a director of a company turning over at least £1 million within the last two years. You have made more than one investment in an unlisted company in the last two years. You have been a member of a network or syndicate of business angels for at least six months. You have worked in the past two years in a professional capacity in the private equity sector or in the provision of finance for small and medium enterprises.